'First-In-Human' directed pre-clinical development of anti-cancer agent CYC140

Cyclacel已经开发出一种临床候选NCE，其特点是能够针对以前未被开发的机制来治疗食道癌(OEC)，这是一种具有高度未满足需求的孤儿疾病。这种有效和选择性的PLK1激酶抑制剂具有强大的临床前理由，可用作OEC和其他具有特定驱动因素突变的固体肿瘤适应症的分层药物。药物开发项目包括用于患者临床分层的标志物分析的临床前验证、“人类首例”(FIH)指导的安全性研究、用于第一阶段测试的临床配方和制造，以及在目标疾病模型中将该化合物与经批准的和研究中的治疗药物结合进行测试。成功将吸引对英国和欧盟开发计划的进一步投资，确保更多的就业机会，并将为患有预后不良疾病的实体肿瘤患者提供一种新的研究药物。

Cyclacel has developed a clinical candidate NCE with characteristics enabling the targeting of a previously unexploited mechanism for treatment of oesophageal cancer (OEC), an orphan disease with a high unmet need. This potent and selective PLK1 kinase inhibitor has a strong preclinical rationale for use as a stratified medicine for OEC and other solid tumour indications having particular driver mutations. The drug development project encompasses preclinical validation of marker assays for clinical stratification of patients, 'First-In-Human' (FIH)-directed safety studies, clinical formulation and manufacture for Phase 1 testing, and testing of the compound in combination with approved and investigational therapeutic agents in models of the target diseases. Success will attract further investment in a UK and EU based development program, securing additional jobs and will provide access to a new investigational medicine for solid tumour patients with poor prognosis diseases.